RIBOCICLIB (RIB) plus LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL

被引：0
|
作者：
Farhat, Fadi [6 ]
Martin, Miguel [7 ]
Campone, Mario [8 ]
Bachelot, Thomas [1 ]
Neven, Patrick [12 ]
Martinez Rodriguez, Jorge Luis [3 ,4 ]
Yusof, Mastura Md [11 ]
Papazisis, Konstantinos [5 ]
Ferreira, Ana [2 ]
Ankrah, Nii [9 ]
Wu, Jiwen [9 ]
Zhou, Katie [9 ]
De laurentiis, Michelino [10 ]
机构：
[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[2] CUF Porto Hosp, Inst CUF Oncol, Porto, Portugal
[3] Escuela Nacl Med, Monterrey, Nuevo Leon, Mexico
[4] Tecnol Monterrey, Monterrey, Nuevo Leon, Mexico
[5] Euromed Gen Clin, Dept Oncol, Thessaloniki, Greece
[6] Hammoud Hosp UMC, Hematol Oncol Div, Saida, Lebanon
[7] Hosp Gregorio Maranon, Dept Oncol, Madrid, Spain
[8] Inst Canc Res Western France ICO, Lyon, France
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Natl Canc Inst, Fdn Pascale, Naples, Italy
[11] Pantai Hosp, Dept Oncol, Kuala Lumpur, Malaysia
[12] Univ Hosp Leuven UZ Leuven, Dept Obstet Gynecol, Leuven, Belgium
来源：
BREAST | 2019年 / 48卷
关键词：
D O I：
10.1016/S0960-9776(19)30676-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO67
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [21] Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
    Campone, Mario
    De Laurentiis, Michelino
    Zamagni, Claudio
    Kudryavcev, Igor
    Agterof, Mariette
    Brown-Glaberman, Ursa
    Palacova, Marketa
    Chatterjee, Sanjoy
    Menon-Singh, Lakshmi
    Wu, Jiwen
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (01) : 95 - 103
  • [22] CompLEEment-1: phase 3b study of ribociclib 1 letrozole for the treatment of hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
    Zamagni, C.
    Martin, M.
    Ring, A.
    Cottu, P.
    Zhou, K.
    Wu, J.
    Zarate, J. P.
    De Laurentiis, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Safety and efficacy of ribociclib (RIBO) plus letrozole (LET) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
    De laurentiis, M.
    Mazza, M.
    Mansutti, M.
    Masetti, R.
    Ballatore, Z.
    Torrisi, R.
    Michelotti, A.
    Zambelli, A.
    Ferro, A.
    Generali, D.
    Vici, P.
    Coltelli, L.
    Fabi, A.
    Marchetti, P.
    Ballestrero, A.
    Spazzapan, S.
    Frassoldati, A.
    Sarobba, G.
    Grasso, D.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Safety analysis of the phase 3b CompLEEment-1 trial
    Lu, Janice
    Cottu, Paul
    Martin, Miguel
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Ankrah, Nii
    De Laurentiis, Michelino
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Cottu, Paul
    Ring, Alistair
    Abdel-Razeq, Hikmat
    Marchetti, Paolo
    Cardoso, Fatima
    Bofill, Javier Salvador
    Martin, Miguel
    Menon-Singh, Lakshmi
    Wu, Jiwen
    De Laurentiis, Michelino
    BREAST, 2022, 62 : 75 - 83
  • [26] Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
    Neven, P.
    Petrakova, K.
    Bianchi, G. V.
    Merino, L. De la Cruz
    Jerusalem, G.
    Beck, J. T.
    Sonke, G. S.
    Chia, S.
    Brucker, S.
    Wang, Y.
    He, W.
    Lorenc, K. Rodriguez
    Su, F.
    Im, S-A.
    ANNALS OF ONCOLOGY, 2018, 29 : 113 - +
  • [27] Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2-advanced breast cancer (ABC).
    DeLaurentiis, Michelino
    Borstnar, Simona
    Campone, Mario
    Warner, Ellen
    Bofill, Salvador
    Jacot, William
    Dent, Susan Faye
    Martin, Miguel
    Ring, Alistair E.
    Cottu, Paul H.
    Lu, Janice M.
    Ciruelos, Eva
    Azim, Hamdy A.
    Chatterjee, Sanjoy
    Zhou, Katie
    Wu, Jiwen
    Ankrah, Nii
    Zamagni, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses
    Hortobagyi, Gabriel N.
    Paluch-Shimon, Shani
    Petrakova, Katarina
    Villanueva, Cristian
    Chan, Arlene
    Nusch, Arnd
    Yap, Yoon Sim
    Hart, Lowell
    Favret, Anne
    Marschner, Norbert
    Sonke, Gabe S.
    Ohnstad, Hege Oma
    Arteaga, Carlos
    Su, Fei
    He, Wei
    Miller, Michelle Kristine
    Stemmer, Salomon M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).
    Hortobagyi, Gabriel N.
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon Sim
    Sonke, Gabe S.
    Paluch-Shimon, Shani
    Campone, Mario
    Petrakova, Katarina
    Blackwell, Kimberly L.
    Winer, Eric P.
    Janni, Wolfgang
    Verma, Sunil
    Conte, Pier Franco
    Arteaga, Carlos L.
    Cameron, David A.
    Xuan, Fengjuan
    Miller, Michelle Kristine
    Germa, Caroline
    Hirawat, Samit
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
    Verma, S.
    Gil-Gil, M.
    Hegg, R.
    Wheatley-Price, P.
    Kattan, J.
    Bourgeois, H.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345